Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... The companies said this is the first time a medicine has shown a clinical benefit in basal cell carcinoma ...